EUVIMEDScopri EUVIMED
Video/Audio

Inhibition of Osteoclastogenesis by LY90009 through Notch Signaling Modulation in Osteolytic Disease Models

Zhaowen Yang, Hailin Du, Bo Miao

Journal of Visualized Experiments · 2025

DOI: 10.3791/69178 ↗

At a glance

Video/Audio in Journal of Visualized Experiments, 2025. Written by Zhaowen Yang and 2 co-authors. Institution: Department of Rheumatology, Central Hospital Affiliated to Shandong First Medical University. Major MEDLINE topics: Osteoclasts, Receptors, Notch, Osteolysis. 41 references.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Dysregulated osteoclast activity profoundly contributes to the progression of osteolytic disease, yet the extent of therapeutic intervention modalities is constrained by adverse effects. This study investigated LY900009, a γ-secretase inhibitor, and its capacity to suppress RANKL-induced osteoclastogenesis through modulation of Notch signaling. Using bone marrow-derived macrophages, we performed comprehensive in vitro evaluations of cytotoxicity, differentiation, and functional assays. Gene and protein expression analyses using qPCR and western blotting were used to elucidate the underlying molecular mechanisms. The in vivo efficacy was corroborated using a murine lipopolysaccharide-induced bone resorption model. LY900009 inhibited RANKL-induced osteoclast formation and resorptive function in a dose-dependent manner without cytotoxicity at therapeutic concentrations. This treatment significantly reduced the number of TRAP-positive osteoclasts, impaired actin belt formation, and suppressed bone matrix degradation. The expression of osteoclast markers, including NFATc1, c-Fos, cathepsin K, and TRAP, was markedly downregulated. Mechanistically, LY900009 disrupted Notch signaling and the downstream MAPK/Akt pathways. In vivo administration substantially reduced LPS-induced bone destruction, improving bone parameters and reducing osteoclast presence. These findings demonstrate that LY900009 effectively inhibits osteoclastogenesis and bone resorption by modulating the Notch/MAPK/Akt signaling axis, making it a promising therapeutic candidate for osteolytic disorders.

Subjects

MeSH terms (MEDLINE)

OsteoclastsReceptors, NotchOsteolysisAnimalsMiceSignal TransductionMice, Inbred C57BLDisease Models, AnimalAmyloid Precursor Protein SecretasesMacrophagesRANK LigandBenzazepinesFluorocarbons

Substances

Receptors, NotchAmyloid Precursor Protein SecretasesRANK Ligand2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamideBenzazepinesFluorocarbons

Authors and institutions

  • Department of Rheumatology, Central Hospital Affiliated to Shandong First Medical University.
  • Department of Geriatrics, Feicheng People's Hospital.
  • Department of Trauma Center, Central Hospital Affiliated to Shandong First Medical University; my13296673295y@163.com.

Cite

APA

Yang, Z., Du, H., & Miao, B. (2025). Inhibition of Osteoclastogenesis by LY90009 through Notch Signaling Modulation in Osteolytic Disease Models. Journal of Visualized Experiments. https://doi.org/10.3791/69178

Vancouver

Yang Z, Du H, Miao B. Inhibition of Osteoclastogenesis by LY90009 through Notch Signaling Modulation in Osteolytic Disease Models. Journal of Visualized Experiments. 2025. doi:10.3791/69178

BibTeX
@article{Yang2025,
  author = {Yang, Zhaowen and Du, Hailin and Miao, Bo},
  title = {Inhibition of Osteoclastogenesis by LY90009 through Notch Signaling Modulation in Osteolytic Disease Models},
  journal = {Journal of Visualized Experiments},
  year = {2025},
  doi = {10.3791/69178}
}
Start for free →